Clinical Trial Update: Intermediate-size Patient Population Expanded Access Protocol

View source ↗

Summary

Spinogenix updated its expanded access protocol for an investigational ALS therapy targeting an intermediate-sized patient population. The update outlines eligi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Snippet

Sponsor: Spinogenix | Conditions: ALS (Amyotrophic Lateral Sclerosis) | Status: AVAILABLE